Samsung Biologics Corporate Governance Report Disclosed: Excellent Transparency but Neutral Impact Due to Lack of Shareholder Return Policy
Board Composition: 7 members including 4 outside directors (majority); audit, compensation, and internal transaction committees fully composed of outside directors ensuring independence
Shareholder Rights: Electronic voting implemented; shareholder proposal process disclosed on website; no dividend paid and not reflected in articles, reducing predictability
Internal Controls: CEO succession policy; compliance management (ISO 37001/37301); internal accounting management system (consolidated) confirmed effective
ESG Performance: KCGS integrated A rating, EcoVadis Platinum, CDP Water Security A, demonstrating global-level sustainable management
[AI Summary]This corporate governance report confirms Samsung Biologics has robust governance with board independence, internal controls, and ESG excellence; however, the absence of direct shareholder return policies such as share buybacks or dividends keeps its impact on shareholder value neutral